Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
CONCLUSIONS: The bevacizumab plus chemotherapy disease control rate for recurrent and metastatic cervical cancer is comparatively high, prolonging median survival; bevacizumab-associated adverse reactions are mild and tolerable.
PMID: 29767869 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
More News: Avastin | Bleeding | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Docetaxel | Hypertension | OBGYN | Statistics | Taxotere | Thrombosis